NIH R01 · 2025
Discovery of novel tau proteoforms as biomarker candidates for AD and PSP
Project Summary Abstract Early detection and diagnosis of Alzheimer’s disease (AD) or Alzheimer’s disease and related dementias (ADRD) have been important goals of the National Plan to Address Alzheimer’s Disease since the first Advisory Council recommendations in 2012. Major breakthroughs have been accomplished over the last 10 years using blood-based biomarkers for amyloid and tau pathologies. Over this time, the Dage lab led the discovery and development of assays for unique phosphorylated proteoforms of tau (P-tau181 and P-tau217) that can differentiate AD from non-AD controls or other neurodegenerative diseases. We have demonstrated that P-tau217 is elevated 2-fold compared with…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.